Case finding for hepatitis C in primary care: A cost utility analysis

Family Practice

Volumn 23, Issue 4, 2006, Pages 393-406

  Thompson Coon, Joanna ^a   Castelnuovo, Emanuela ^a   Pitt, Martin ^a   Cramp, Matthew ^d   Siebert, Uwe ^b,c   Stein, Ken ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^d DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Case finding; Cost benefit analysis; Hepatitis C; Intravenous substance abuse; Primary health care

Indexed keywords

ALGORITHM; ARTICLE; COMORBIDITY; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; HEALTH CARE COST; HEPATITIS C; HUMAN; PRIMARY HEALTH CARE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SUBSTANCE ABUSE; UNITED KINGDOM; VIROLOGY;

ALGORITHMS; COMORBIDITY; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; GREAT BRITAIN; HEALTH CARE COSTS; HEPATITIS C; HUMANS; MARKOV CHAINS; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 39049193681     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cml032     Document Type: Article

References (26)

1. Department of Health. Hepatitis C Strategy for England. 2002.
2. Consensus Conference on Hepatitis C. Royal college of Physicians of Edinburgh Consensus Statement. J Viral Hepat 2004; 11(Suppl 1)2-4.
3. Health Protection Agency, SCIEH, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB, the UASSG. Shooting Up; Infections among Injecting Drug Users in the United Kingdom 2003. London: Health Protection Agency; 2004.
4. Health Protection Agency. Supplementary data tables of the Unlinked Anonymous Survey of Injecting Drug Users in contact with services: Data to the end of 2003. Department of Health; 2004.
5. Thompson J. Audit improves access to care for drug users with hepatitis C. Guidelines in Practice 2002; 5: 39-52.
6. Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
7. Stein K, Dalziel K, Walker A et al. Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess 2002; 6: 1-122.
8. Sculpher M, Pang FS, Manca A et al. Generalisability in economic evaluation studies in healthcare: A review and case studies. Health Technol Assess 2004; 8.
9. Bird SM, Goldberg DJ, Hutchinson SJ. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data. J Epidemiol Biostat 2001; 6: 243-265.
10. Mohsen AH, Group TH, Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001; 48: 707-713.
11. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: An analysis of the literature. J Viral Hepat 2001; 8: 87-95.
12. Serfaty M, Lawrie A, Smith B et al. Risk factors and medical follow-up of drug users tested for hepatitis C - can the risk of transmission be reduced? Drug Alcohol Rev 1997; 16: 339-347.
13. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000; 14: 543-548.
14. Curtis L, Netten A. Unit costs of Health and Social Care; 2004.
15. Wright M, Grieve R, Roberts J, Main J, Thomas H, on behalf of the UK mild hepatitic C trial investigators. Health Benefits of anti-viral therapy for mild chronic hepatitis C. 95/24/03. 2005.
16. Irving WL, Smith S, Cater R et al. Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. J Viral Hepat 2006; 13: 264-271.
17. Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm. BMJ 1997; 315: 453-458.
18. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 2004; 8: 1-140.
19. Beich A, Thorsen T, Rollnick S. Screening in brief intervention trials targeting excessive drinkers in general practice: A systematic review and meta-analysis. BMJ 2003; 327: 536-543.
20. British National Formulary. British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2004.
21. Transplant Activity in the UK, 2003-2004. Transplant UK, Statistics and Audit Directorate; 2004.
22. Planas R, Balleste B, Alvarez MA et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40: 823-830.
23. Office for National Statistics. Cancer survival trends in England and Wales, 1971-1995: Deprivation and NHS Region.
24. Neumann UP, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004; 77: 226-231.
25. Mortality statistics: Cause (SeriHs DH2) 2002. Available at: http://www.statistics.gov.uk/STATBASE/Productasp?vlnk=618&More=Y [2002 [cited 2004]; Series DH2 Mortality Statistics (On-line edition).
26. Office of National Statistics (Department of Health; National Assembly of Wales; Information and Statistics Division, NHS Scotland; Central Services Agency, Northern Ireland). General practitioners, dentists and options by NMS Regional Office area, 30 September 2001: Regional Trends 37 (RT37719).